COPD合并Ⅱ型呼吸衰竭患者外周血HMGB1 IL-17及呼出气一氧化氮浓度对预后的预测价值

doi:10.3969/j.issn.1006-6233.2023.09.010

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1777 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the changes of high mobility group protein B1 (HMGB1), interleukin-17 (IL-17) and exhaled nitric oxide (FeNO) levels in peripheral blood of patients with chronic obstructive pulmonary disease (COPD) combined with respiratory failure type II, and to analyze its predictive value for prognosis. Methods: A total of 100 patients with COPD combined with respiratory failure type II in our hospital from January 2021 to December 2022 were selected as the observation group, 60 patients with COPD but without respiratory failure during the same period were selected as the control group, and 60 patients with healthy physical examination were selected as the healthy group. Peripheral blood HMGB1, IL-17 and FeNO were collected upon admission. Patients were classified as dead or alive based on survival at 28 days of hospitalization, and peripheral blood was analyzed for HMGB1, IL-17, and FeNO. The clinical influencing factors of prognosis were analyzed by Lasso-Logistic regression. To analyze the effect of FeNO interaction with peripheral blood HMGB1 and IL-17 on the prognosis of patients and its predictive value for prognosis. Results: Peripheral blood HMGB1, IL-17 and FeNO were higher in the observation group than in the control group and the healthy group, and the control group was higher than the healthy group (P<0.05); there was a positive correlation between peripheral blood HMGB1, IL-17 and FeNO (P<0.05); the proportion of acute exacerbations ≥2, the APACHE II score, peripheral blood HMGB1, IL-17 and FeNO were independent prognostic risk factors (P<0.05); there was an interaction between high expression of HMGB1, IL-17, and FeNO and poor prognosis (P<0.05); and the AUC of the combination of HMGB1, IL-17, and FeNO in predicting prognosis was higher than that predicted by the index alone (P<0.05). Conclusion: The peripheral blood concentrations of HMGB1, IL-17 and FeNO were elevated in patients with COPD combined with type II respiratory failure and had synergistic effects in poor prognosis, and the combined detection of their levels to predict prognosis has clinical application value.

Key words： Chronic obstructive pulmonary disease Type II respiratory failure High mobility group protein B1 Interleukin-17 Exhaled nitric oxide

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.09.010 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I9/1459

[1] Ferrera MC,Labaki WW,Han MK.Advances in chronic obstructive pulmonary disease[J].Annu Rev Med,2021,72(1):119-134.
[2] Yang IA,Jenkins CR,Salvi SS.Chronic obstructive pulmonary disease in never-smokers:risk factors,pathogenesis,and implications for prevention and treatment[J].Lancet Respir Med,2022,10(5):497-511.
[3] Sun J,Li Y,Ling B,et al.High flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure:an observational cohort study[J].Int Chron Obstruct Pulmon Dis,2019,14(1):1229-1237.
[4] Lin L,Li J,Song Q,et al.The role of HMGB1/RAGE/TLR4 signaling pathways in cigarette smoke-induced inflammation in chronic obstructive pulmonary disease[J].Immun Inflamm Dis,2022,10(11):711-721.
[5] Ding F,Han L,Fu Q,et al.IL-17 aggravates pseudomonas aeruginosa airway infection in acute exacerbations of chronic obstructive pulmonary disease[J].Front Immunol,2022,12(1):811803-811813.
[6] Zhou A,Zhou Z,Deng D,et al.The value of FENO measurement for predicting treatment response in patients with acute exacerbation of chronic obstructive pulmonary disease[J].Int Chron Obstruct Pulmon Dis,2020,15(1):2257-2266.
[7] Zhang M,Lu Y,Liu L,et al.Role and mechanism of miR-181a-5p in mice with chronic obstructive pulmonary disease by regulating HMGB1 and the NF-κB pathway[J].Cells Tissues Organs,2022,24(1):1-10.
[8] Mao Y,Patial S,Saini Y.Airway epithelial cell-specific deletion of HMGB1 exaggerates inflammatory responses in mice with muco-obstructive airway disease[J].Front Immunol,2023,13(1):944772-944782.
[9] Zhu R,Xie X,Wang N,et al.The T helper type 17/regulatory T cell imbalance was associated with Ras-GTPase overexpression in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease[J].Immunology,2019,157(4):304-311.
[10] Ambrosino P,Fuschillo S,Accardo M,et al.Fractional exhaled nitric oxide (FeNO) in patients with stable chronic obstructive pulmonary disease:short-term variability and potential clinical implications[J].Pers Med,2022,12(11):1906-1916.
[11] Raja W,Ahmed N,Rizvi NA,et al.Comparison of DECAF (dysponea,eosinopenia,consolidation,acidaemia,and atrial fibrillation) and APACHE II (acute physiology and chronic health evaluation ii) scoring system to predict mortality among patients with acute exacerbation of chronic obstructive pulmonary disease[J].Pak Med Assoc,2021,71(8):1935-1939.